Air china baggage policy international flights

American Airlines said it is restarting passenger flights to China on Wednesday, lifting the total number of U.S. weekly flights to 10. The U.S. government continues pushing for more air traffic between the world's two largest economies. Flora Bradley-Watson reports. Reports of an Apple car shed light on QuantumScape, an up and coming car battery maker. Investor's Business DailyThe Dow Jones fell ahead of President Donald Trump signing the new $900 billion coronavirus stimulus bill. The bill is now awaiting President Trump's signature. How much will you get - and when? The conventional wisdom is that we are on the cusp of another big stock market rally. 2020 has been a volatile year with the unprecedented coronavirus recession in February and March, followed by a bull running through the summer and fall, with increased volatility in late fall as investors tried to make sense of the election and the second wave of viruses. But it's all past. The choice is settled, Congress will be divided so narrowly that major legislative initiatives are unlikely, and the long-awaited COVID vaccines are starting to come into circulation. In short, we have a combination of risk and reward establishment, for investors willing to put some skin in the game. And for those who are really ready to take on the extra risk, penny stocks may be the right choice for a bigger rally. These stocks are priced low, below $5 per share, and low prices are usually done for a good reason. But some penny stocks are fundamentally healthy, and with their low price already baked in, they have nowhere to go but up. Using the TipRanks database, we've pulled up details on two compelling stocks that fit this profile of low share price and huge upside potential, 200% or more, according to Wall Street analysts. Not to mention, both boast a Strong Buy consensus rating. Palatin Technologies (PTN) We start with Palatin Technologies, a biopharmaceutical company with a unique niche and a competitive advantage. Palatin specializes in the development of melanocortin and natriuretic peptide receptor systems. These are a new class of potential medications, receptor-specific and highly targeted to specific diseases. Palatin has drugs in development for dry eye disease, obesity, and congestive heart failure. Palatin's pipeline has more immediate uses, as well - PL8177, originally developed to target ulcerative colitis, has recently entered Phase 1 trials as a treatment for COVID-19. For the competitive advantage, Palatin has Vyleesi. Vyleesi is the marketing brand bremelanotide, the first melanocortin peptide treatment for premenopausal women with generalized hypoactive sexual desire disorder. Fda considers Vyleesi a 'first in class' drug, and approved it for use in June Palatin has been marketing Vyleesi in North America since then. I I This year, Palatin settled a legal dispute with AMAG Pharmaceutical in which Palatin regained all North American legal rights to Vyleesi, along with a $16.3 million settlement, of which $12 million has already been paid out. Currently going for $0.42 apiece, Canaccord analyst John Newman believes the share price presents an attractive entry point. Vyleesi continues to make commercial progress, ensure broader insurance reimbursement coverage and strengthen relationship with healthcare providers [...] Palatin continues to look for potential U.S. re-licenses for Vyleesi to improve commercialization. Any re-licensing/partnership could revolve around a business currently in the female health care products market. We believe that a new re-licensing agreement could carry a meaningful prepayment, since Vyleesi has full FDA approval, the 5-star analyst believed. On top of this, Palatin announced phase 2 data from its PL9643 dry eye disease (DED) exploratory study last week. Newman points out that the results showed statistically significant improvement in several signs and symptoms in the moderate to severe patient population. Palatin plans to begin phase 2/3 trials in mid-2021. In keeping with his bullish stance, Newman rates PTN a Buy, and his $3 price target implies room for a whooping 615% upside potential in the next 12 months. (Click here to see Newman's results.) Overall, Palatin gets a Strong Buy rating from the analyst consensus and that verdict is unanimous, based on 3 recent Buy reviews. The average price target, $2.17, implies an impressive 417% upside for the year ahead. (See PTN stock analysis on TipRanks) Mustang Bio (MBIO)Mustang Bio is another clinical stage biopharmaceutical company. Mustang's focus is on potential cures for blood cancers, solid tumors, and genetic diseases, using medical breakthroughs in cell and gene therapies to create targeted medications. The company is actively developing CAR-T (Chimeric antigen receptor T-cells) treatments as treatments for non-Hodgkin's leukemia and other cancers. Mustang has a robust research pipeline, with gene therapies, hematological CAR-Ts, and solid tumor CAR-Ts in development to treat a wide range of diseases. Preclinical research is ongoing and phase 1 and 2 trials are scheduled for 2023. The company has six clinical trials underway for conditions ranging from glioblastomas to multiple myeloma to prostate cancer. The company's clinical phase drug, MB-106, shows promise as a treatment for non-Hodgkin's Leukemia.In his detailed review of the company for B. Riley Securities, analyst Justin Zelin notes the early success of MB-106, and its potential for the company going forward. We see MB-106's robust power at 89% overall response rate (ORR) and 44% complete response rate (CRR) a highly favorable safety profile in n=9 NHL-treated patients patients Mustang's modified cell manufacturing process as a significant positive de-risking event for the program and mustang's platform in general. On the heels of this positive data set, Mustang will file an Investigativeal New Drug (IND) application in 1Q21E to enable the initiation of a multi-arm multicenter phase II study of MB-106, providing an of-risk detection pathway for approval in CD20+ NHL patients, Zelin wrote. On the bottom line, Zelin is bullish on the Mustang, writing: We continue to believe Mustang Bio is undervalued compared to peers due to a historical lack of catalysts and clinical data that is now changing with positive clinical data presentations. Zelin's comments sapped his Buy rating, and his $13 price target indicates room for up to 300% growth next year. (Click here to see Zelin's results.) Mustang is another penny stock with a unanimous Strong Buy rating, this one based on 4 recent buy reviews. The company's shares sell for $3.16 and have an average price target of $10.75, suggesting an upside of 235% on the one-year time frame. (See MBIO stock analysis on TipRanks) To find great ideas for penny stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Investor's Business DailyCanoo had its stock market debut Tuesday, while Lordstown said it has 80,000 reservations for its electric pickup truck. With another round of stimulus checks of $600 announced by Congress on Sunday, will the Internal Revenue Service give me a check based on my 2019 return? Investors Business DailyLidar shares like Velodyne and Luminar Technologies are soaring on a report that Apple could make a self-driving car by 2024. Ouster is aiming for an SPAC merger. Health-care shares trade at discounted valuations and make up less than 14% of the S&P 500's market weighting. That seems unlikely, says Citigroup.MicroVision 'is essentially a scientific project that has gone nowhere after 25 years,' says short-seller Hindenburg Research.The realized volatility of AT&T's options, which expires in three months, is priced at among the highest levels in five years. It's a possibility. Investor's Business DailySupercharged Nio stock taps demand for electric cars. Here's what the basic and technical analysis says about buying Nio shares now. Every week, Benzinga conducts a sentiment survey to find out what shoppers are most excited about, interested in or thinking about when managing and building their Portfolios. We surveyed a group of over 200 investors on whether shares in Palantir (NYSE: PLTR) will $50 by 2022.Palantir Stock Forecast Palantir provides big data analytics software solutions for U.S. government projects. Palantir released its Gotham software platform in 2008, the platform that focuses primarily on providing data analytics solutions to the U.S. government's intelligence and defense sectors. The company also provides non-governmental organizations with solutions to manage large different data sets in an effort to gain insight and drive operational results. Palantir's stock debuted September 30 at $10 a share and is trading around $28 at the time of release; 78% of Benzinga investors said Palantir would reach $50 per share by the end of 2022.Traders and investors who participated in the survey said Palantir's stock would rise off new and continuing partnerships with the U.S. government and defense-related projects. Though Palantir has yet to turn a financial profit in its 17-year history, Benzinga readers see Palantir leadership, including co-founder and CEO Alex Karp, accelerating revenue growth in the short term. See also: Top 10 Blue Chip Stocks.This survey was conducted by Benzinga in December 2020 and included the responses of a diverse population of adults 18 or older. It was entirely voluntary to choose the survey without any incentives being offered to potential respondents. The study reflects the findings of over 200 adults. Photo courtesy: Cory Doctorow via FlickrSee more from Benzinga * Click here for options trades from Benzinga * Thinking of buying stock in Palantir, FuboTV, Apple, Shopify or Snowflake? * Thinking of buying stock in Palantir, Nio, Carnival, Plug Power or Moderna? (C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. During the pandemic, 27% of Americans have slowed or stopped saving for the future. After a true annus horribilus, we are all ready for better times. The U.S. stock strategy team at Goldman Sachs, led by David Kostin, sees the better time ahead, and in the short term. The team predicts a 25 percent gain for the S&P 500 in the next 24 months - or to put it in absolute terms, they believe the index will hit 4,600 by December 2022. Kostin lays four clear reasons to believe we are at the start of another prolonged bull run. Firstly, he notes the generally improved economic conditions; secondly, he points to the growth in corporate earnings; third, are the historically low interest rates that the Fed adheres to its near-zero interest rate policy; and finally there is TINA, or 'there is no alternative.' Stocks are heading into a virtuous circle, Kostin believes, as they offer the highest returns available for now. In a recent interview, Goldman's chief equity strategist said of these points, It's the story, it's about an economy that's getting better, that's out pandemic, and generally gets better, and fed on hold. All this is for and I think the market recognizes that and will continue to do so. Goldman Sachs analysts are following Kostin's lead, and point out three stocks that they believe will gain from the overall market increase. We ran the trio through TipRank's database to see what other Wall Street analysts have to say about them. Lordstown Motors (RIDE)The first Goldman choice is Lordstown Motors. This Ohio-based company, closely linked to The Big 3 standard General Motors, is an electric car maker. The company is working out of GM's old Lordstown, Ohio assembly plant, which it bought last year. Lordstown boasts over 6.2 million square feet of production floor space, and a capacity of 600,000 vehicles a year. The company's flagship vehicle is the all-wheel drive Endurance pickup truck. The vehicle is based on a unique design, using individual electric motors on each wheel hub. The Endurance is scheduled for delivery in autumn 2021.Founded in 2018, Lordstown Motors was announced earlier this year through a merger with a 'blank cheque' company. These transactions are designed to raise capital for companies wishing to enter the public market. As part of preparations to release its Endurance truck, Lordstown has entered into an agreement with Camping World Holdings (CWH), the RV maker. Camping World will train its mechanics on the new truck, and provide garage floor space for Lordstown's customers. The agreement includes potentials for expansion, such as sharing sales, space and delivery of electric drive systems for camper vans. Covering this stock for Goldman Sachs, analyst Mark Delaney writes: We believe this collaboration is a first step to addressing Lordstown's service footprint and charging infrastructure, and we see Lordstown's decision to leverage an existing service footprint as a cost-effective strategy... We believe the broader customer experience, including service and charging, plays an important role in product differentiation and can help EV start-ups succeed. In our opinion, the ease and reliability of maintenance and charging is particularly important for Lordstown's fleet/commercial customer base, which is focused on vehicle uptime. In line with these comments, Delaney rates RIDE shares a Buy along with a $31 price target for the next 12 months. At current levels, this implies a potential 67% upside. (Click here to see Delaney's results.) Overall, RIDE shares are getting a hold from analyst consensus that reflects Wall Street's caution toward a new - and highly speculative - endeavor. The rating is derived from 4 recent reviews, evenly split between 2 Buyer and 2 Sells. But the $27.50 average price target suggests that RIDE has a 48% upside for the year ahead. (See RIDE stock analysis on TipRanks) Liberty Global (LBTYA)Next up is Liberty holding company in the telecommunications sector. Liberty has a one the presence of operations in seven European countries: the United Kingdom, the Netherlands, Ireland, Belgium, Poland, Slovakia and Switzerland. The company boasts annual revenues of over $11 billion. Through its subsidiaries, Liberty serves over 11 million customers with a total of 25 million subscriptions to broadband Internet, TV and telephone services. The company also claims 6 million mobile and wifi subscribers. Liberty is a leading investor in European digital and online infrastructure projects. Among the company's latest moves was the acquisition of Swiss telecoms provider Sunrise Communications last month. With the completion of the transactions, Liberty Global now owns over 98% of Sunrise's total share capital, making the Swiss company a wholly owned subsidiary of Liberty Global Group.Goldman Sachs analyst Andrew Lee, in a comprehensive review of Liberty's current business and market position, points to the Swiss acquisition as a key factor for the company's future. He writes: We see Sunrise as a quality asset with sustained growth potential for market share. We expect this will benefit LBTYA directly as Sunrise continues to win a share from Swisscom, but also to help stabilize the UPC asset. Lee gives LBTYA shares a Buy rating along with a $33 price target. This figure implies ~36% one-year upside from the current level. (Click here to see Lee's results.) Like RIDE above, Liberty has an even split among its recent reviews – in this case, 3 Buys and 2 Holder, making the analyst consensus look a Moderate Buy. The shares are priced at $24.32, and the average price target of $30.12 indicates room for ~24% growth from that level. (See LBTYA stock analysis on TipRanks) Lufax Holding (LU) Fintech is a rapidly growing niche, and Lufax operates a personal financial services platform serving the Chinese market. The company provides wealth management for the fast-growing middle class in China, a population that is not only growing in size but also in wealth. Lufax offers financing solutions for personal and business loans to this population, which is not always well served by China's established banking sector. The company's customer base includes small business owners and employees. Revenue for the third quarter, reported earlier this month, came in at $2 billion in U.S. currency. EPS of 24 cents beat estimates by 10 cents, or 71%. However, these figures had fallen year on year. The biggest uncertainty that Lufax is facing at the moment is state regulation. China's government, while maintaining a market-based economy, is keeping a tight grip on economic activity in general, and modern, cutting-edge companies like Lufax can run on edge with regulators who are sometimes uncomfortable with the digital world. The prospect of regulation, which officials seek to impose controls on fintech, has some investors worried. After a comprehensive comprehensive of the Chinese tech regulatory framework, Goldman's Elsie Cheng, covering Lufax, noted: We remain constructive on Lufax's ability to navigate through the ever-changing regulatory environment and deliver consistent value-add to its consumers/financial partners. In light of that Cheng rates LU a Buy along with a $20 price target, implying a 34% upside for the coming year. (Click here to see Cheng's results.) Overall, moderate buy analyst consensus rating on Lufax is based on 7 reviews, including 4 Buys and 3 Holds. The average price target of $17.70 indicates a potential 15% upside next year. (See LU stock analysis on TipRanks) To find great ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. While the world has been focused on the notable recent public market debuts for DoorDash and Airbnb, the real fireworks have been around the astonishing reception of C3.ai.Investor's Business DailyWhen weighs oil stocks to buy, consider which is diversified and which is focused more on shale or specific regions. Real estate investment trusts (REITs) are listed companies that allow individual investors to purchase shares in property portfolios that receive income from a number of properties. They allow investors to easily invest in the real estate sector, which includes companies that own, develop and manage residential, commercial and industrial properties. The coronavirus pandemic crisis shows no signs of abating, even with a vaccine coming into the markets. We still face serious social lockdown policies, with a number of states (such as California, Minnesota, and Michigan) forcing even tougher restrictions on this round than in the past. It's a severe blow to the leisure industry, which is still reeling from one of the most difficult years in memory. The difficulties faced by restaurants are getting more press, but for the cruise industry, Corona has been a perfect storm. Prior to the pandemic, the cruise industry - which had been doing business for $150 billion annually - was expected to carry 32 million passengers by 2020. It's all gone now. Over the summer, the industry rolled as more than 3,000 COVID cases were linked to 123 separate cruise ships, resulting in 34 deaths. After such a difficult year, it is helpful to step back and take a snapshot of the state of the industry. JPMorgan analyst Brandt Montour has in a comprehensive review of the cruise industry in general and three cruise line giants in particular. We believe that equities may continue to grind higher in the short term, driven overwhelmingly by the broader vaccine background/progress. Looking further, operators will face plenty of headwinds when restarting/ramping operations in 2Q3Q21, but a significant sequential improvement in revenue/cash flows during this period will likely dominate the narrative, and we think investors will continue to see through short-term setbacks to a 2022 characterized by fully ramped capacity, near full occupancy, and hitherto manageable pricing pressure, Mont. Against this backdrop, Montour has picked out two stocks that are worth the risk and one that investors should avoid for now. Using TipRanks' Stock Comparison tool, we lined up the three side by side to get the lowdown on what the short-term holds for these cruise line players. Royal Caribbean (RCL)The second largest cruise line, Royal Caribbean, is still a top pick for Montour and his company. The company has put its resources into meeting and meeting the challenges of the pandemic, which has provided liquidity and both streamlined and modernized the fleet. Maintaining liquidity has been the most pressing issue. While the company has resumed some cruising, and has even taken delivery of a new ship, the Silver Moon, most operations remain suspended. For Q3, the company reported adjusted earnings of -$5.62, below consensus of -$5.17. Management estimates that the cash assistance will be between $250 million and $290 million a month. To combat this, RCL reported having $3.7 billion in liquidity at the end of September. That included $3 billion in cash on hand along with $700 million available through a credit facility. Total cash flow at the end of Q3 decreased more than 9% from the end of Q2. Since the third quarter ended, RCL has added over $1 billion to its cash position, through an issue of $500 million senior notes and a sale of shares, putting an additional 8.33 million shares on the market at $60 each. In his note on Royal Caribbean, Montour writes, [We] are most constructive at OW-rated RCL, which we believe has the most compelling set of demand drivers... its extensive investments in premium priced new hardware, as well as consumer data, all set RCL up well to grow the industry in revenue metrics, profit margins, and ROIC in the longer term. Montour backs its Overweight (i.e. purchase) rating with a $91 price target. This figure represents an upside of 30% for 2021. (Click here to see Montour's results.) Does the rest of the street agree? As it turns out, analyst consensus is more of a mixed bag. 4 Buy ratings and 6 Holder give RCL a Moderate Buy status. Meanwhile, the stock is selling for $69.58 per share, just over the $68.22 average price target. (See RCL Norwegian Cruise Line (NCLH) With a market value of $7.45 billion and a fleet of 28 ships, Norwegian Cruise Line found its smaller size as an advantage in this pandemic time. With a smaller and newer fleet, fixed costs, especially ship maintenance, were lower. These benefits do not mean that the company has avoided the storm. Earlier this month, Norwegian announced an extension of its sailing policy covering all scheduled journeys from 1 January 2021 to 28 February 2021 plus selected voyages in March 2021. The cancellations come as Norwegian's revenue is down - in the third quarter, the top line was just $6.5 million, compared with $1.9 billion in the same quarter a year ago. The company also reported a cash incineration of $150 million a month. In november and December, Norwegian took steps to improve liquidity. The company closed on $850 million in senior notes, at 5.875% and due in 2026, in November, and earlier this month closed a offering of common stock. The stock's offer amounted to 40 million shares at $20.80 per share. Together, the two deals raised more than $1.6 billion in new capital. More positively, Norwegian is preparing for a possible resumption of full service. The company announced, on December 7, a partnership with AtmosAir Solutions for the installation of air purification systems on all 28 vessels in its current fleet, using filtration technology known to defeat coronavirus. JPM's Montour points out these benefits in its review of Norwegian, and summarizes the bottom line: This combined with a relatively newer, higher end, brand/ship footprint will generally lead us to believe that it was in a good position to outperform on pricing growth, although its demographic bias to older age customers is likely to remain a hindrance through 2021. Ultimately, NCLH is a high-quality asset within the broader cruise industry, with a higher beta for a cruise recovery, and it should look outperformance as the industry returns and investors look further out of the risk spectrum. Montour gives the stock a price target of $30 and an overweight (i.e. purchase) rating. His target implies an upside of 27% on the one-year time frame. Norwegian is another cruise line with a Moderate Buy from the analyst consensus. This rating is based on 4 purchases, 4 vices and 1 sell set in recent months. Like the RCL above, the share price here, $23.55, is currently higher than the average price target, $23.22. (See NCLH stock analysis on TipRanks) Carnival Corporation (CCL)Last up, Carnival, is the world's largest cruise line, with a market value of $23.25 billion, more than 100 ships across its brands, and over 700 destination ports. In normal times, this gigantic footprint gave the company an advantage; Now, however, it has become an expensive responsibility. This is shown by the Company's Q3 fiscal assistance approaching 770 Dollar. Like the other major cruise companies, Carnival has extended its boat cancellations, or expression, pause in operations. The Cunard line, one of Carnival's brands, has cancelled travel on the Queen Mary 2 and Queen Elizabeth through early June next year. Carnival has also canceled operations in February from the ports of Miami, Galveston and Port Canaveral, and pushed back the inaugural voyage of the new ship Mardi Gras to the end of April 2021. These measures were taken in accordance with coronavirus restrictions. Carnival's shares and revenue are suffering heavy losses this year. The stock has fallen 60% year-to-date, despite some recent price demonstrations since late October. Revenue fell to just $31 million in the fiscal third quarter, reported in September. Carnival reported a loss of nearly $3 billion this quarter. The company ended the third quarter with over $8 billion in available cash, an impressive resource to cope with the difficult situation. This combination of strength and weakness led Montour to set a neutral (i.e. hold) rating on CCL shares. But his $25 price target suggests a possible upside of 23%. Commenting on Carnival, Montour wrote: [We] believe that some of the same relative net profit pulls it so in 2018-2019 due to its large size will likely be top of the mind on the other side of this crisis... But given CCL's relative share discount, lower price growth ahead of the crisis, and geographic diversification, we see it as the company with the slightest downside over the next few months and are not surprised by its recent outperformance. We believe that this will reverse in 2H21. Overall, Carnival has a Hold rating from analyst consensus. This rating is based on 10 reviews that break down to 1 Buy, 8 vices and 1 sell. The stock sells for $20.28 and its $18.86 average price target implies a disadvantage potential of ~7%. (See CCL stock analysis on TipRanks) To find great ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Investors Business DailyCostco stock continues to thrive despite pressure from e-commerce competition. As retail stock giant grows, should you climb on board COST stock? The national debate over student loan forgiveness has shifted into high gear. Last month, Sen. Chuck Schumer called for the elimination of up to $50,000 of student loan debt, joining a chorus of activists for debt forgiveness. Not to be outdone, the Secretary of Education just extended a pandemic-inspired moratorium on student loans Payments. Payments.